{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:33:06Z","timestamp":1778621586944,"version":"3.51.4"},"reference-count":149,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Millennium: The Takeda Oncology Company","award":["12G2664"],"award-info":[{"award-number":["12G2664"]}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["10429"],"award-info":[{"award-number":["10429"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.clml.2014.04.011","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T23:01:12Z","timestamp":1402527672000},"page":"356-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee"],"prefix":"10.1016","volume":"14","author":[{"given":"Noopur","family":"Raje","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Faiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Donald","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra E.","family":"Kurtin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Conde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-5165","authenticated-orcid":false,"given":"Marie Sabo","family":"Recine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene R.","family":"Tombler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.04.011_bib1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib3","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1200\/JCO.2003.07.200","article-title":"Treatment of plasma cell dyscrasias with thalidomide and its derivatives","volume":"21","author":"Dimopoulos","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib4","unstructured":"National Comprehensive Cancer Network (NCCN) Highlights of the First Annual NCCN Hematologic Malignancies Congress. Multiple myeloma: recent advances in induction therapy and transplant options (2006)."},{"key":"10.1016\/j.clml.2014.04.011_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib7","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib8","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib9","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib10","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib11","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for\u00a0relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib12","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for\u00a0relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib14","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib15","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of\u00a0autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib17","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib18","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/10428194.2010.531409","article-title":"Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)","volume":"52","author":"Venner","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.04.011_bib20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib21","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib22","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A\u00a0randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib23","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomized controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2014.04.011_bib24","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: a network meta-analysis","author":"Mhaskar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 1","key":"10.1016\/j.clml.2014.04.011_bib25","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0145-2126(12)70007-3","article-title":"How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events","volume":"36","author":"Mateos","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.04.011_bib26","unstructured":"Kumar SK, Dispenzieri A, Gertz MA, et\u00a0al. Continued improvement in survival in multiple myeloma and the impact of novel agents. Poster presented at the 54th ASH Annual Meeting and Exposition, Atlanta, GA, December 8-11,\u00a02012."},{"key":"10.1016\/j.clml.2014.04.011_bib27","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Multiple myeloma. Version 2.2014. November 8,\u00a02013. Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed July 8, 2014."},{"key":"10.1016\/j.clml.2014.04.011_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/17474086.2014.870030","article-title":"An overview of the progress in the treatment of multiple myeloma","volume":"7","author":"Kyle","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2014.04.011_bib29","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1158\/1078-0432.CCR-12-1881","article-title":"New strategies in the treatment of multiple myeloma","volume":"19","author":"Munshi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.04.011_bib30","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.seminoncol.2013.07.004","article-title":"The future of drug development and therapy in myeloma","volume":"40","author":"Lonial","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3324\/haematol.2013.083592","article-title":"Multiple myeloma: so much progress, but so many unsolved questions","volume":"98","author":"Moreau","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.04.011_bib32","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2013-01-481291","article-title":"Pursuing the curative blueprint for early myeloma","volume":"122","author":"Roschewski","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib33","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib34","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11899-013-0185-y","article-title":"Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any?","volume":"8","author":"Giralt","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2014.04.011_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12185-013-1294-z","article-title":"Current approaches for the treatment of multiple myeloma","volume":"97","author":"Watanabe","year":"2013","journal-title":"Int J Hematol"},{"issue":"suppl 2","key":"10.1016\/j.clml.2014.04.011_bib37","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0305-7372(10)70006-2","article-title":"Multiple myeloma - current issues and controversies","volume":"36","author":"Kumar","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2014.04.011_bib38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1548-5315(11)70790-2","article-title":"The NCCN guidelines: how do they relate to community oncology practice?","volume":"1","author":"Powers","year":"2004","journal-title":"Community Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib39","first-page":"161","article-title":"Baseline institutional compliance with NCCN guidelines: non\u2013small-cell lung cancer","volume":"11","author":"Walsh","year":"1997","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2014.04.011_bib40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1245\/s10434-007-9789-6","article-title":"Compliance with melanoma treatment guidelines in a community teaching hospital: time trends and other variables","volume":"15","author":"Erickson","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2007.0010","article-title":"Implementation of NCCN distress management guidelines by member institutions","volume":"5","author":"Jacobsen","year":"2007","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2014.04.011_bib42","first-page":"525","article-title":"A\u00a0breast center review of compliance with National Comprehensive Cancer Network Breast Cancer guidelines","volume":"192","author":"Landercasper","year":"2006","journal-title":"Am J\u00a0Surg"},{"issue":"11","key":"10.1016\/j.clml.2014.04.011_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.2613.2613","article-title":"Practice patterns in the diagnosis of follicular lymphoma: report from the National Lymphocare Study","volume":"110","author":"Matasar","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib44","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1200\/JCO.2001.19.11.2886","article-title":"Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways","volume":"19","author":"Smith","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib45","unstructured":"Public Health Agency of Canada. Canadian Strategy for Cancer Control. 2001. Draft Synthesis Report. Ottawa."},{"key":"10.1016\/j.clml.2014.04.011_bib46","first-page":"485","article-title":"Adoption of state-of-the-art therapy","volume":"17","author":"Ford","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.2010.31.6414","article-title":"Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines","volume":"29","author":"Poonacha","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2014.04.011_bib48","article-title":"Barriers to clinical practice guidelines adherence in the community oncology setting","volume":"29","author":"Shah","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib49","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.091083","article-title":"Oncologists' experience in reporting cancer staging and guideline adherence: lessons from the 2006 Medicare Oncology Demonstration","volume":"6","author":"Doherty","year":"2010","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2014.04.011_bib50","series-title":"Transforming clinical Research in the United States. Challenges and Opportunities: Workshop Summary. Institute of Medicine (US) Forum on Drug Discovery, Development and Translation","year":"2010"},{"key":"10.1016\/j.clml.2014.04.011_bib51","series-title":"Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis","author":"National Research Council","year":"2013"},{"key":"10.1016\/j.clml.2014.04.011_bib52","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","article-title":"Future of cancer incidence in the United\u00a0States: burdens upon an aging, changing nation","volume":"27","author":"Smith","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib53","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.04.011_bib54","first-page":"148","article-title":"Clinical aspects of multiple myeloma and related disorders including amyloidosis","volume":"47","author":"Kyle","year":"1999","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.clml.2014.04.011_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib56","first-page":"9","article-title":"Cancer Statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2014.04.011_bib57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib58","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2014.04.011_bib59","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2012-05-432203","article-title":"Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma","volume":"121","author":"Bergsagel","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1053\/j.seminoncol.2013.08.001","article-title":"Individualized therapy in multiple myeloma: are we there?","volume":"40","author":"Girnius","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjh.12519","article-title":"Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma","volume":"163","author":"Sarasquete","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.04.011_bib62","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00277-013-1757-6","article-title":"Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation","volume":"92","author":"Terragna","year":"2013","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2014.04.011_bib63","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1517\/14712598.2013.793305","article-title":"Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing","volume":"13","author":"Agnelli","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clml.2014.04.011_bib64","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib65","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2013-08-520890","article-title":"Smoldering multiple myeloma requiring treatment: time for a new definition?","volume":"122","author":"Dispenzieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib66","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-12-2922","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease","volume":"19","author":"Agarwal","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.04.011_bib67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/17474086.2014.874944","article-title":"How long can we let the myeloma smolder?","volume":"7","author":"Usmani","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2014.04.011_bib69","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrclinonc.2013.160-c1","article-title":"Treatment of smoldering multiple myeloma","volume":"10","author":"Gozzetti","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3174.3174","article-title":"Phase II trial of initial safety and toxicity prior to the phase iii trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma (e3a06): a trial coordinated by the Eastern Cooperative Oncology Group","volume":"122","author":"Lonial","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib71","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a\u00a0biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib72","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","author":"P\u00e9rez-Persona","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.04.011_bib73","unstructured":"US Food and Drug Administration (FDA). Drug Approvals and Data Bases\/Approvals. Pomalidomide. Available at: www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm339286.htm. Accessed September 3,\u00a02013."},{"key":"10.1016\/j.clml.2014.04.011_bib74","unstructured":"US Food and Drug Administration (FDA). Drug Approvals and Data Bases\/Approvals. Carfilzomib. Available at: www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm312945.htm. Accessed September 3,\u00a02013."},{"key":"10.1016\/j.clml.2014.04.011_bib75","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib76","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: a multicenter phase 1\/2 open-label study","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib77","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib78","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","article-title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma","volume":"119","author":"Vij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib79","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"Phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib80","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1471-2407-12-415","article-title":"Design and rationale of FOCUS(PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R\/R MM)","volume":"12","author":"H\u00e1jek","year":"2012","journal-title":"BMC Cancer"},{"issue":"suppl","key":"10.1016\/j.clml.2014.04.011_bib81","article-title":"Medical oncologists' clinical experiences and comfort levels with 20 recently approved agents","volume":"31","author":"Love","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib82","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/2040620711432020","article-title":"Safety and efficacy of subcutaneous formulation of\u00a0bortezomib versus the conventional intravenous formulation in multiple myeloma","volume":"3","author":"Mateos","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2014.04.011_bib83","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.04.011_bib84","first-page":"190","article-title":"Novel treatment paradigm for elderly patients with multiple myeloma","volume":"1","author":"Palumbo","year":"2011","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.clml.2014.04.011_bib85","first-page":"307","article-title":"Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents","volume":"4","author":"Kurtin","year":"2013","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib86","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1586\/14737140.2014.856269","article-title":"Optimal management of elderly patients with myeloma","volume":"14","author":"Cerrato","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2014.04.011_bib87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11899-013-0177-y","article-title":"Incorporating novel agents in the management of elderly myeloma patients","volume":"8","author":"Guglielmelli","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2014.04.011_bib88","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group Consensus Statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib89","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Leleu X, Palumbo A, et\u00a0al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia, Published online February 5, 2014. http:\/\/dx.doi.org\/10.1038\/leu.2014.60.","DOI":"10.1038\/leu.2014.60"},{"key":"10.1016\/j.clml.2014.04.011_bib90","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00432-013-1570-6","article-title":"How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study","volume":"140","author":"Huang","year":"2014","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib91","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/asheducation-2013.1.488","article-title":"How should we treat newly diagnosed multiple myeloma patients?","volume":"2013","author":"Mateos","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2014.04.011_bib92","series-title":"Velcade [package insert]","year":"2012"},{"key":"10.1016\/j.clml.2014.04.011_bib93","first-page":"406","article-title":"Subcutaneous administration of bortezomib: strategies to reduce injection site reactions","volume":"3","author":"Kurtin","year":"2012","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib94","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4065\/83.10.1142","article-title":"Treatment of myeloma: cure vs control","volume":"83","author":"Rajkumar","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2014.04.011_bib95","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2.2","article-title":"Initial phase 3 results of the first\u00a0(frontline investigation of lenalidomide\u00a0+ dexamethasone versus standard thalidomide) trial (MM-020\/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT)","volume":"122","author":"Facon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib96","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/annonc\/mdt509","article-title":"Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents","volume":"25","author":"Merz","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib97","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.2013.087585","article-title":"Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial","volume":"99","author":"Scheid","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.04.011_bib98","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib99","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib100","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/cncr.26422","article-title":"Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.04.011_bib101","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3109\/10428194.2012.751528","article-title":"Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma","volume":"54","author":"Dunavin","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.04.011_bib102","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib103","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/17474086.2014.878645","article-title":"The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients","volume":"7","author":"McCarthy","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2014.04.011_bib104","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.seminoncol.2013.07.008","article-title":"New developments in post-transplant maintenance treatment of multiple myeloma","volume":"40","author":"Liu","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib105","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib106","doi-asserted-by":"crossref","first-page":"35","DOI":"10.6004\/jnccn.2013.0006","article-title":"Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation","volume":"11","author":"McCarthy","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2014.04.011_bib107","doi-asserted-by":"crossref","first-page":"43","DOI":"10.6004\/jnccn.2013.0007","article-title":"Part II: role of maintenance therapy in transplant-ineligible patients","volume":"11","author":"Palumbo","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2014.04.011_bib108","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.406.406","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005-02 trial","volume":"122","author":"Attal","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib109","doi-asserted-by":"crossref","unstructured":"Landgren O, Mailankody S. Update on second primary malignancies in multiple myeloma: a focused review. Leukemia, Published online January 14, 2014. http:\/\/dx.doi.org\/10.1038\/leu.2014.22.","DOI":"10.1038\/leu.2014.22"},{"key":"10.1016\/j.clml.2014.04.011_bib110","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib111","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.011_bib112","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/asheducation.V2013.1.496.3847117","article-title":"Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients","volume":"2013","author":"McCarthy","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2014.04.011_bib113","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1586\/17474086.2014.858595","article-title":"Future agents and treatment directions in multiple myeloma","volume":"7","author":"Ocio","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2014.04.011_bib114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1586\/17474086.2014.882764","article-title":"Current strategies for treatment of relapsed\/refractory multiple myeloma","volume":"7","author":"Laubach","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2014.04.011_bib115","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1200\/JCO.2009.24.3683","article-title":"Relapse\/refractory myeloma patient: potential treatment guidelines","volume":"27","author":"San Miguel","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib116","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/bjc.2013.113","article-title":"Drivers and barriers to patient participation in RCTs","volume":"108","author":"Jenkins","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2014.04.011_bib117","first-page":"10","article-title":"News Letter of the Multiple Myeloma Research Foundation (MMRF). Oncology survey results. Oncologist Survey Indicates Need to Educate Physicians and Patients about Clinical Trials","volume":"5","year":"2004","journal-title":"Myeloma Focus"},{"key":"10.1016\/j.clml.2014.04.011_bib118","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1200\/JCO.2007.14.8114","article-title":"Influence of clinical communication on patients' decision making on participation in clinical trials","volume":"26","author":"Albrecht","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib119","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cct.2011.09.005","article-title":"Nurse practitioners' attitudes about cancer clinical trials and willingness to recommend research participation","volume":"33","author":"Ulrich","year":"2012","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.clml.2014.04.011_bib120","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.ejca.2005.10.033","article-title":"Why don't cancer patients enter clinical trials? A review","volume":"42","author":"Castel","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2014.04.011_bib121","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/sj.bjc.6606004","article-title":"The attitudes of 1066 patients with cancer towards participation in randomised clinical trials","volume":"103","author":"Jenkins","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2014.04.011_bib122","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12012","article-title":"What issues matter most to\u00a0people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools","volume":"89","author":"Osborne","year":"2012","journal-title":"Eur J Haematol"},{"issue":"suppl","key":"10.1016\/j.clml.2014.04.011_bib123","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1188\/13.CJON.S2.13-24","article-title":"Autologous hematopoietic stem cell transplantation for patients with multiple myeloma: an overview for nurses in community practice","volume":"17","author":"Miceli","year":"2013","journal-title":"Clin J Oncol Nurs"},{"issue":"suppl","key":"10.1016\/j.clml.2014.04.011_bib124","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1188\/13.CJON.S2.25-32","article-title":"Caregivers of multiple myeloma survivors","volume":"17","author":"Kurtin","year":"2013","journal-title":"Clin J Oncol Nurs"},{"issue":"suppl 3","key":"10.1016\/j.clml.2014.04.011_bib125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1188\/08.CJON.S1.53-62","article-title":"IMF Nurse Leadership Board. Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Faiman","year":"2008","journal-title":"Clin J Oncol Nurs"},{"issue":"suppl 3","key":"10.1016\/j.clml.2014.04.011_bib126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1188\/08.CJON.S1.37-51","article-title":"Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Smith","year":"2008","journal-title":"Clin J Oncol Nurs"},{"issue":"suppl","key":"10.1016\/j.clml.2014.04.011_bib127","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1188\/11.S1.CJON.5-8","article-title":"Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the International Myeloma Foundation Nurse Leadership Board","volume":"15","author":"Bilotti","year":"2011","journal-title":"Clin J Oncol Nurs"},{"issue":"suppl","key":"10.1016\/j.clml.2014.04.011_bib128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1188\/11.S1.CJON.9-23","article-title":"Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board","volume":"15","author":"Miceli","year":"2011","journal-title":"Clin J Oncol Nurs"},{"issue":"suppl","key":"10.1016\/j.clml.2014.04.011_bib129","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1188\/11.CJON.S1.66-76","article-title":"Renal complications in multiple myeloma\u00a0and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board","volume":"15","author":"Faiman","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clml.2014.04.011_bib130","unstructured":"International Myeloma Foundation. Nurse Leadership Board. Available at: http:\/\/myeloma.org\/PortalPage.action?tabId=8&menuId=201&portalPageId=7. Accessed May 6,\u00a02013."},{"key":"10.1016\/j.clml.2014.04.011_bib131","first-page":"26","article-title":"Medication self-management: important concepts for advanced practitioners in oncology","volume":"2","author":"Faiman","year":"2011","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib132","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib133","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.04.011_bib134","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12185-011-0948-y","article-title":"The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma","volume":"94","author":"Johnson","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2014.04.011_bib135","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/blood-2011-03-342089","article-title":"Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib136","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1038\/leu.2012.128","article-title":"SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status","volume":"26","author":"L\u00f3pez-Corral","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib137","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2013.49.2124","article-title":"Minimal residual disease in multiple myeloma","volume":"31","author":"Munshi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib138","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib139","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by\u00a0multiparameter flow cytometry in multiple myeloma: impact on outcome in\u00a0the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.011_bib140","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00259-011-1993-8","article-title":"18F-FDG PET\/CT for detection and\u00a0localization of residual or recurrent disease in patients with multiple myeloma\u00a0after stem cell transplantation","volume":"39","author":"Derlin","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2014.04.011_bib141","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/leu.2013.306","article-title":"The current status of minimal residual disease assessment in myeloma","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.011_bib142","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging \u201cearly myeloma\u201d","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.04.011_bib143","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","article-title":"Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.04.011_bib144","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a\u00a0promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.04.011_bib145","first-page":"409","article-title":"PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex\u00a0vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.clml.2014.04.011_bib146","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the\u00a0natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib147","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.04.011_bib148","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.011_bib149","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"De Weers","year":"2010","journal-title":"J\u00a0Immunol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:03Z","timestamp":1761870363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014001554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":149,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S2152265014001554"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.04.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}